Plant Name: Zingiber spectabile
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| CTDSP1; TDP1; PTGES; NOS2; AKR1B1; HSD17B2; ALOX15; NOX4; HSD17B1; USP2; | |
| PRKCE; RPS6KA3; DAPK1; MAPK1; FLT3; EGFR; | |
| CA2; CA1; CA12; CA9; CA13; CA5B; CA7; CA4; CA6; | |
| AR; | |
| ESRRA; | |
| ALOX5; TYR; XDH; | |
| BACE1; | |
| MMP9; ANPEP; | |
| TLR9; | |
| HIF1A; TP53; AHR; | |
| EP300; | |
| ABCG2; ABCC1; | |
| NFE2L2; LMNA; F3; APP; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Aspartic protease | BACE1 | Beta-secretase 1 | P56817 | CHEMBL4822 |
| ATP-binding cassette | ABCG2 | ATP-binding cassette sub-family G member 2 | Q9UNQ0 | CHEMBL5393 |
| ATP-binding cassette | ABCC1 | Multidrug resistance-associated protein 1 | P33527 | CHEMBL3004 |
| Bromodomain | EP300 | Histone acetyltransferase p300 | Q09472 | CHEMBL3784 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
| Enzyme_unclassified | CTDSP1 | Carboxy-terminal domain RNA polymerase II polypeptide A small phosphatase 1 | Q9GZU7 | CHEMBL1795098 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | PTGES | Prostaglandin E synthase | O14684 | CHEMBL5658 |
| Enzyme_unclassified | NOS2 | Nitric oxide synthase, inducible | P35228 | CHEMBL4481 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
| Enzyme_unclassified | USP2 | Ubiquitin carboxyl-terminal hydrolase 2 | O75604 | CHEMBL1293227 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA13 | Carbonic anhydrase XIII | Q8N1Q1 | CHEMBL3912 |
| Lyase | CA5B | Carbonic anhydrase VB | Q9Y2D0 | CHEMBL3969 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
| Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
| Metallo protease | ANPEP | Aminopeptidase N | P15144 | CHEMBL1907 |
| Nuclear hormone receptor subfamily 3 group B | ESRRA | Estrogen-related receptor alpha | P11474 | CHEMBL3429 |
| Nuclear hormone receptor subfamily 3 group C | AR | Androgen Receptor | P10275 | CHEMBL1871 |
| Oxidoreductase | ALOX5 | Arachidonate 5-lipoxygenase | P09917 | CHEMBL215 |
| Oxidoreductase | TYR | Tyrosinase | P14679 | CHEMBL1973 |
| Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
| Protein Kinase | PRKCE | Protein kinase C epsilon | Q02156 | CHEMBL3582 |
| Protein Kinase | RPS6KA3 | Ribosomal protein S6 kinase alpha 3 | P51812 | CHEMBL2345 |
| Protein Kinase | DAPK1 | Death-associated protein kinase 1 | P53355 | CHEMBL2558 |
| Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Protein Kinase | EGFR | Epidermal growth factor receptor erbB1 | P00533 | CHEMBL203 |
| Toll-like and Il-1 receptors | TLR9 | Toll-like receptor 9 | Q9NR96 | CHEMBL5804 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Transcription Factor | AHR | Aryl hydrocarbon receptor | P35869 | CHEMBL3201 |
| Unclassified | NFE2L2 | Nuclear factor erythroid 2-related factor 2 | Q16236 | CHEMBL1075094 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | F3 | Coagulation factor III | P13726 | CHEMBL4081 |
| Unclassified | APP | Beta amyloid A4 protein | P05067 | CHEMBL2487 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 2.125E-11 | 2.571E-08 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 2.266E-10 | 2.145E-07 | ALOX15, ALOX5, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, NOS2, XDH |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 8.383E-10 | 6.519E-07 | ANPEP, AR, CA1, CA12, CA13, CA2, CA4, CA5B, CA6, CA7, CA9, EP300, ESRRA, MMP9, TP53 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 1.467E-09 | 1.030E-06 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, NOX4 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 1.681E-09 | 1.109E-06 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 3.242E-08 | 1.336E-05 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, NOS2, NOX4 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 3.052E-07 | 8.744E-05 | CYP1A2, CYP2C19, CYP2C9 |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 3.123E-07 | 8.831E-05 | CYP1A1, CYP1A2, CYP1B1, NFE2L2 |
| CC | GO:0044464; cell part | GO:0005641; nuclear envelope lumen | 8.514E-07 | 1.931E-04 | ALOX5, APP, PTGES |
| BP | GO:0009987; cellular process | GO:0071276; cellular response to cadmium ion | 1.093E-06 | 2.454E-04 | CYP1A2, EGFR, MAPK1, MMP9 |
| BP | GO:0048511; rhythmic process | GO:0007623; circadian rhythm | 1.189E-06 | 2.616E-04 | AHR, EGFR, EP300, NOS2, TP53, USP2 |
| BP | GO:0009987; cellular process | GO:0071407; cellular response to organic cyclic compound | 2.585E-06 | 5.361E-04 | APP, AR, CYP1A1, CYP1B1, EGFR, FLT3, MAPK1, NOX4 |
| BP | GO:0008152; metabolic process | GO:2000379; positive regulation of reactive oxygen species metabolic process | 3.184E-06 | 6.082E-04 | EGFR, NFE2L2, NOX4, TP53, XDH |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 3.321E-06 | 6.234E-04 | CYP1A2, CYP2C19, CYP2C9 |
| CC | GO:0044464; cell part | GO:0048471; perinuclear region of cytoplasm | 4.185E-06 | 7.470E-04 | AKR1B1, APP, CA4, EGFR, NOS2, NOX4, PRKCE, PTGES, TYR, USP2 |
| BP | GO:0023052; signaling | GO:0032230; positive regulation of synaptic transmission, GABAergic | 4.310E-06 | 7.630E-04 | CA2, CA7, PRKCE |
| BP | GO:0050896; response to stimulus | GO:0009725; response to hormone | 4.990E-06 | 8.624E-04 | AKR1B1, AR, CA2, CA9, CYP1A2, EGFR, ESRRA, FLT3, NFE2L2, PRKCE |
| BP | GO:0009987; cellular process | GO:0071456; cellular response to hypoxia | 6.488E-06 | 1.070E-03 | HIF1A, LMNA, NFE2L2, PRKCE, TP53 |
| CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 7.290E-06 | 1.150E-03 | ABCC1, CA2, CA4, CA9, EGFR, TLR9 |
| MF | GO:0005488; binding | GO:0001085; RNA polymerase II transcription factor binding | 1.106E-05 | 1.606E-03 | AHR, AR, EP300, NFE2L2, TP53 |
| BP | GO:0009987; cellular process | GO:2001234; negative regulation of apoptotic signaling pathway | 1.496E-05 | 2.101E-03 | AR, DAPK1, HIF1A, LMNA, MMP9, NFE2L2 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 1.888E-05 | 2.538E-03 | CA2, CA7 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 2.622E-05 | 3.439E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0009987; cellular process | GO:0071345; cellular response to cytokine stimulus | 2.952E-05 | 3.782E-03 | ALOX15, DAPK1, FLT3, HIF1A, MAPK1, NFE2L2, NOS2 |
| BP | GO:0008152; metabolic process | GO:0036003; positive regulation of transcription from RNA polymerase II promoter in response to stress | 2.991E-05 | 3.786E-03 | HIF1A, NFE2L2, TP53 |
| BP | GO:0032501; multicellular organismal process | GO:0032640; tumor necrosis factor production | 3.770E-05 | 4.486E-03 | APP, TLR9 |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 3.770E-05 | 4.486E-03 | CYP1A1, CYP1A2 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 3.770E-05 | 4.486E-03 | CYP1A2, CYP2C9 |
| BP | GO:0009987; cellular process | GO:1901522; positive regulation of transcription from RNA polymerase II promoter involved in cellular response to chemical stimulus | 4.806E-05 | 5.537E-03 | EP300, HIF1A, NFE2L2 |
| BP | GO:0050896; response to stimulus | GO:1901655; cellular response to ketone | 5.267E-05 | 6.004E-03 | AKR1B1, AR, EGFR, PRKCE |
| BP | GO:0009987; cellular process | GO:2000045; regulation of G1/S transition of mitotic cell cycle | 5.521E-05 | 6.203E-03 | CTDSP1, CYP1A1, EGFR, EP300, TP53 |
| BP | GO:0050896; response to stimulus | GO:0033273; response to vitamin | 5.526E-05 | 6.203E-03 | CYP1A1, EGFR, TP53, TYR |
| BP | GO:0050896; response to stimulus | GO:0071417; cellular response to organonitrogen compound | 5.809E-05 | 6.389E-03 | AKR1B1, APP, EGFR, MAPK1, NFE2L2, NOX4, TP53 |
| BP | GO:0008152; metabolic process | GO:0006691; leukotriene metabolic process | 6.559E-05 | 7.081E-03 | ABCC1, ALOX15, ALOX5 |
| BP | GO:0008152; metabolic process | GO:1901615; organic hydroxy compound metabolic process | 7.802E-05 | 8.207E-03 | AKR1B1, ALOX15, APP, CYP1A1, CYP1B1, HIF1A, TYR |
| BP | GO:0002376; immune system process | GO:0002682; regulation of immune system process | 8.178E-05 | 8.490E-03 | AHR, ALOX15, APP, CA2, EP300, ESRRA, HIF1A, MAPK1, NFE2L2, PRKCE, RPS6KA3, TLR9, TP53 |
| MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 8.686E-05 | 8.913E-03 | CYP1A1, CYP2C19, CYP2C9 |
| CC | GO:0016020; membrane | GO:0005789; endoplasmic reticulum membrane | 8.718E-05 | 8.913E-03 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, EGFR, HSD17B2, NOX4, PTGES, TLR9 |
| BP | GO:0008152; metabolic process | GO:2001300; lipoxin metabolic process | 9.395E-05 | 9.356E-03 | ALOX15, ALOX5 |
| MF | GO:0003824; catalytic activity | GO:0004064; arylesterase activity | 9.395E-05 | 9.356E-03 | CA1, CA2 |
| BP | GO:0065007; biological regulation | GO:0030641; regulation of cellular pH | 9.819E-05 | 9.631E-03 | CA2, CA7, MAPK1, TP53 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 9.875E-21 | 2.150E-16 | CA1, CA12, CA13, CA2, CA4, CA5B, CA6, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 1.786E-16 | 1.296E-12 | CA1, CA12, CA13, CA2, CA4, CA5B, CA6, CA7, CA9 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 1.325E-15 | 5.771E-12 | CA1, CA12, CA13, CA2, CA4, CA5B, CA6, CA7, CA9 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 3.495E-20 | 5.278E-18 | CA12; CA1; CA5B; CA2; CA4; CA7; CA6; CA9; CA13 |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 3.496E-08 | 2.526E-06 | AR; NOS2; FLT3; DAPK1; EP300; MAPK1; HIF1A; TP53; MMP9; EGFR |
| hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 5.019E-08 | 2.526E-06 | DAPK1; MAPK1; MMP9; TP53; EGFR |
| hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 1.396E-07 | 5.269E-06 | HSD17B1; ALOX5; HSD17B2; CYP1A1; CYP1B1 |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 3.097E-07 | 7.795E-06 | CYP2C9; APP; ALOX5; ALOX15; MAPK1; CYP2C19 |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 4.170E-07 | 8.995E-06 | CYP2C9; ALOX5; ALOX15; CYP2C19; PTGES |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 5.722E-07 | 1.035E-05 | ABCC1; PRKCE; CYP1B1; EP300; MAPK1; TP53; MMP9; EGFR |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 2.974E-07 | 7.795E-06 | HSD17B1; CYP1A2; HSD17B2; CYP1A1; CYP1B1 |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 9.918E-07 | 1.362E-05 | NOS2; ALOX15; AKR1B1; CYP2C19; TYR; CYP2C9; ANPEP; HSD17B1; ALOX5; HSD17B2; CYP1A2; CYP1A1; XDH; PTGES |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 6.166E-07 | 1.035E-05 | FLT3; MAPK1; TP53; HIF1A; EGFR |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 2.545E-06 | 2.957E-05 | AR; EP300; MAPK1; TP53; EGFR |
| hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 5.232E-06 | 5.644E-05 | NOS2; EP300; MAPK1; HIF1A; EGFR |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 1.695E-06 | 2.133E-05 | CYP2C9; CYP1A2; CYP1A1; CYP1B1; CYP2C19 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 7.218E-07 | 1.090E-05 | CYP2C9; CYP1A2; ALOX15; CYP2C19 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 3.056E-05 | 3.076E-04 | CYP2C9; CYP1A2; CYP1A1; CYP1B1 |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 1.360E-04 | 1.141E-03 | MAPK1; TP53; HIF1A; MMP9; EGFR |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 1.987E-04 | 1.579E-03 | EP300; MAPK1; TP53; HIF1A |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 2.120E-04 | 1.600E-03 | ABCC1; PRKCE; MAPK1; TP53 |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 4.474E-04 | 2.815E-03 | EP300; MAPK1; TP53; MMP9 |
| hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 1.281E-04 | 1.138E-03 | CYP1A2; CYP1A1; CYP1B1 |
| hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 3.497E-04 | 2.400E-03 | MAPK1; TP53; EGFR |
| hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 2.807E-04 | 2.018E-03 | MAPK1; TP53; EGFR |
| hsa05214 | Glioma_Homo sapiens_hsa05214 | 5.425E-04 | 2.954E-03 | MAPK1; TP53; EGFR |
| hsa04150 | mTOR signaling pathway_Homo sapiens_hsa04150 | 4.287E-04 | 2.814E-03 | RPS6KA3; MAPK1; HIF1A |
| hsa05211 | Renal cell carcinoma_Homo sapiens_hsa05211 | 5.674E-04 | 2.954E-03 | EP300; MAPK1; HIF1A |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 5.674E-04 | 2.954E-03 | MAPK1; TP53; EGFR |
| hsa05152 | Tuberculosis_Homo sapiens_hsa05152 | 9.403E-04 | 4.303E-03 | NOS2; TLR9; EP300; MAPK1 |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 5.425E-04 | 2.954E-03 | CYP2C9; CYP1A2; CYP1A1 |
| hsa04720 | Long-term potentiation_Homo sapiens_hsa04720 | 5.674E-04 | 2.954E-03 | RPS6KA3; EP300; MAPK1 |
| hsa05218 | Melanoma_Homo sapiens_hsa05218 | 7.026E-04 | 3.422E-03 | MAPK1; TP53; EGFR |
| hsa04933 | AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | 1.946E-03 | 7.685E-03 | PRKCE; MAPK1; F3 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 6.463E-04 | 3.253E-03 | CYP2C9; CYP1A2; CYP2C19 |
| hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 1.838E-03 | 7.685E-03 | MAPK1; MMP9; EGFR |
| hsa04916 | Melanogenesis_Homo sapiens_hsa04916 | 1.891E-03 | 7.685E-03 | EP300; MAPK1; TYR |
| hsa04520 | Adherens junction_Homo sapiens_hsa04520 | 7.928E-04 | 3.741E-03 | EP300; MAPK1; EGFR |
| hsa05231 | Choline metabolism in cancer_Homo sapiens_hsa05231 | 1.946E-03 | 7.685E-03 | MAPK1; HIF1A; EGFR |
| hsa04010 | MAPK signaling pathway_Homo sapiens_hsa04010 | 3.487E-03 | 1.170E-02 | RPS6KA3; MAPK1; TP53; EGFR |
| hsa05142 | Chagas disease (American trypanosomiasis)_Homo sapiens_hsa05142 | 2.115E-03 | 7.985E-03 | NOS2; TLR9; MAPK1 |
| hsa05145 | Toxoplasmosis_Homo sapiens_hsa05145 | 3.027E-03 | 1.088E-02 | NOS2; ALOX5; MAPK1 |
| hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 3.174E-03 | 1.115E-02 | RPS6KA3; MAPK1; TP53 |
| hsa04114 | Oocyte meiosis_Homo sapiens_hsa04114 | 3.403E-03 | 1.168E-02 | AR; RPS6KA3; MAPK1 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 4.889E-03 | 1.538E-02 | LMNA; MAPK1; TP53 |
| hsa04068 | FoxO signaling pathway_Homo sapiens_hsa04068 | 4.237E-03 | 1.361E-02 | EP300; MAPK1; EGFR |
| hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 4.237E-03 | 1.361E-02 | MAPK1; TP53; EGFR |
| hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 8.083E-03 | 2.393E-02 | BACE1; APP; MAPK1 |
| hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 9.752E-03 | 2.778E-02 | FLT3; TP53; MMP9 |
| hsa05168 | Herpes simplex infection_Homo sapiens_hsa05168 | 1.050E-02 | 2.883E-02 | TLR9; EP300; TP53 |
| hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 1.383E-02 | 3.541E-02 | EP300; MAPK1; TP53 |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 1.383E-02 | 3.541E-02 | MAPK1; TP53 |
| hsa04350 | TGF-beta signaling pathway_Homo sapiens_hsa04350 | 1.804E-02 | 4.394E-02 | EP300; MAPK1 |
| hsa04012 | ErbB signaling pathway_Homo sapiens_hsa04012 | 1.927E-02 | 4.437E-02 | MAPK1; EGFR |
| hsa05140 | Leishmaniasis_Homo sapiens_hsa05140 | 1.383E-02 | 3.541E-02 | NOS2; MAPK1 |
| hsa04912 | GnRH signaling pathway_Homo sapiens_hsa04912 | 2.096E-02 | 4.655E-02 | MAPK1; EGFR |
| hsa04666 | Fc gamma R-mediated phagocytosis_Homo sapiens_hsa04666 | 2.183E-02 | 4.778E-02 | PRKCE; MAPK1 |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 8.613E-03 | 2.501E-02 | FLT3; MAPK1 |
| hsa05222 | Small cell lung cancer_Homo sapiens_hsa05222 | 1.886E-02 | 4.437E-02 | NOS2; TP53 |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 1.312E-02 | 3.538E-02 | CA2; ABCG2 |
| hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 1.013E-02 | 2.831E-02 | MAPK1; TP53 |
| hsa04640 | Hematopoietic cell lineage_Homo sapiens_hsa04640 | 1.969E-02 | 4.437E-02 | FLT3; ANPEP |
| hsa04146 | Peroxisome_Homo sapiens_hsa04146 | 1.764E-02 | 4.366E-02 | NOS2; XDH |
| hsa05132 | Salmonella infection_Homo sapiens_hsa05132 | 1.886E-02 | 4.437E-02 | NOS2; MAPK1 |
| hsa04540 | Gap junction_Homo sapiens_hsa04540 | 1.969E-02 | 4.437E-02 | MAPK1; EGFR |
| hsa05133 | Pertussis_Homo sapiens_hsa05133 | 1.456E-02 | 3.665E-02 | NOS2; MAPK1 |
| hsa04930 | Type II diabetes mellitus_Homo sapiens_hsa04930 | 6.173E-03 | 1.864E-02 | PRKCE; MAPK1 |
| hsa02010 | ABC transporters_Homo sapiens_hsa02010 | 5.209E-03 | 1.605E-02 | ABCC1; ABCG2 |
| hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 2.289E-03 | 8.429E-03 | MAPK1; TP53 |
| hsa04320 | Dorso-ventral axis formation_Homo sapiens_hsa04320 | 1.985E-03 | 7.685E-03 | MAPK1; EGFR |
| hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 1.440E-03 | 6.394E-03 | CA2; CA4 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 5.853E-05 | 5.523E-04 | CYP1A2; XDH |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | EGFR |
| C00-D49: Neoplasms | Inflammatory breast cancer | C50 | EGFR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ALOX5 |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | TLR9 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
| J00-J99: Diseases of the respiratory system | Influenza virus | J11.1 | TLR9 |
| A00-B99: Certain infectious and parasitic diseases | Infections | A00-B99 | TLR9 |
| C00-D49: Neoplasms | Esophageal cancer | C15 | EGFR |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3 |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3 |
| Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | AR |
| C00-D49: Neoplasms | Locally advanced head and neck cancer | C07-C14, C32, C33 | EGFR |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | EGFR; TLR9 |
| A00-B99: Certain infectious and parasitic diseases | Lymphatic filariasis | B74 | ALOX5 |
| H00-H59: Diseases of the eye and adnexa | Macular degeneration | H35.3 | APP |
| C00-D49: Neoplasms | Advanced prostate cancer | C61 | AR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Endocrine disease | E00-E35 | AR |
| NA: NA | Edema | NA | CA2 |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | ALOX5; ALOX5; NOS2; TLR9; TLR9; ESRRA |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | ESRRA |
| C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3; TLR9 |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53 |
| J00-J99: Diseases of the respiratory system | Adult respiratory distress syndrome | J80 | F3 |
| C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | AR |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1 |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | ALOX5 |
| C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | EGFR; TLR9 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | AR |
| C00-D49: Neoplasms | Ovarian cancer | C56 | EGFR; EGFR |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | TP53 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | AKR1B1 |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| C00-D49: Neoplasms | CLL | NA | FLT3 |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | FLT3; EGFR; F3 |
| NA: NA | HIV infections | NA | AHR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic kidney disease | E11.22 | NOS2 |
| I00-I99: Diseases of the circulatory system | Cerebral amyloid angiopathy | I68.0 | APP |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | EGFR |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; CA4 |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | PRKCE; FLT3; TLR9 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ALOX5; ESRRA |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatological disease | L00-L99 | AR; ESRRA |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Vulnerary | S00-T98 | EGFR |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | AR |
| H00-H59: Diseases of the eye and adnexa | Choroidal neovascularisation | H35 | ESRRA |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1 |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | NFE2L2; EGFR; EGFR |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | ALOX5; NOS2 |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; CA4 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Cystic fibrosis | E84 | AR |
| G00-G99: Diseases of the nervous system G00-G99 | Diagnostic imaging | G30, I73.9 | APP |
| J00-J99: Diseases of the respiratory system | Respiratory disease | J00-J99 | ALOX5 |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1; NOS2 |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | TLR9 |
| C00-D49: Neoplasms | Cancer | C00-C96 | AR; HIF1A; TP53; CA1; FLT3; FLT3; CA9; MAPK1; MMP9; EGFR; APP; TLR9 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cachexia | R64 | AR; ESRRA |
| K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | EGFR; ESRRA |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; CA9; EGFR |
| C00-D49: Neoplasms | Refractory breast cancer | C50 | EGFR |
| C00-D49: Neoplasms | Castration-resistant prostate cancer | C61 | AR |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | AR |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3 |
| NA: NA | GIST | NA | FLT3 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Endotoxic shock | R57.8 | NOS2 |
| C00-D49: Neoplasms | Glioblastoma multiforme | C71 | EGFR; EGFR; TLR9 |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3 |
| C00-D49: Neoplasms | Glioma | C71 | EGFR; EGFR; APP |
| NA: NA | Geographic retinal atrophy | NA | APP |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | CA1; CA1; AKR1B1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | XDH; AKR1B1; ABCC1; ABCC1 |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| C00-D49: Neoplasms | Bladder cancer | C67 | AR; EGFR |
| C00-D49: Neoplasms | Advanced cancers | C00-C96 | EGFR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | ALOX5 |
| N00-N99: Diseases of the genitourinary system | Prostate hyperplasia | N40 | AR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | ALOX5; FLT3; EGFR; ANPEP |
| C00-D49: Neoplasms | Breast cancer | C50 | AR; FLT3; FLT3; CA9; EGFR; EGFR; EGFR |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Brain injury | S09.90 | APP |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | EGFR; EGFR |
| G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
| C00-D49: Neoplasms | Head and neck squamous cell carcinoma | C44 | EGFR |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53; EGFR; EGFR; EGFR; AKR1B1 |
| A00-B99: Certain infectious and parasitic diseases | HCV infection | B17.1, B18.2 | TLR9 |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | AR; XDH |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | AR; NOS2 |
| H00-H59: Diseases of the eye and adnexa | Ocular inflammation | H16.229 | NFE2L2 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | HIF1A; TP53; FLT3; CA9; MAPK1; MMP9; EGFR; TLR9 |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MMP9 |
| C00-D49: Neoplasms | Urethral cancer | NA | EGFR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Male hormonal deficiencies | E20-E35 | AR |
| A00-B99: Certain infectious and parasitic diseases | Septic shock | A41.9 | NOS2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | ESRRA |
| C00-D49: Neoplasms | Multiple myeloma | C90 | AHR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | ALOX5 |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | TYR |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | ALOX5; TYR; AKR1B1; ESRRA |
| J00-J99: Diseases of the respiratory system | Rhinitis | J00, J30, J31.0 | ALOX5 |
| C00-D49: Neoplasms | Female androgenresponsive recurrent mammary cancer | C50 | AR |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Muscle atrophy | M62.5 | AR |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | ALOX5 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | ALOX5; ABCC1; ESRRA |
| I00-I99: Diseases of the circulatory system | Bleeding | I74, I80-I82 | F3 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | EGFR |
| C00-D49: Neoplasms | Prostate cancer | C61 | AR; AR; FLT3; EGFR |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9 |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | ALOX5 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Testosterone deficiency | E29.1 | AR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Melasma | L81.1 | TYR |
| C00-D49: Neoplasms | Melanoma | C43 | TYR; EGFR |
| C00-D49: Neoplasms | Malignant tumor | C00-C75, C7A, C7B | EGFR |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | APP; PTGES |
| L00-L99: Diseases of the skin and subcutaneous tissue | Alopecia | L65.9 | AR |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | ALOX5; TLR9 |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | TLR9; ESRRA |
| C00-D49: Neoplasms | AML | NA | FLT3 |
| C00-D49: Neoplasms | Colon cancer | C50 | FLT3; EGFR |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | TP53; FLT3; MMP9; EGFR; EGFR; TLR9 |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | APP |
| I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9 |
| NA: NA | Male hypogonadism | NA | AR |
| H00-H59: Diseases of the eye and adnexa | Age related macular degeneration | H35.3 | APP |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3 |
| K00-K95: Diseases of the digestive system | Alcoholic hepatitis | K70.1 | AR |
| I00-I99: Diseases of the circulatory system | Coronary artery disease | I20-I25 | NOS2 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | AR; AR; ESRRA |
| A00-B99: Certain infectious and parasitic diseases | Cryptosporidium infection | A07.2 | EGFR |
| G00-G99: Diseases of the nervous system G00-G99 | Mild to moderate alzheimer disease | G30 | APP |
| C00-D49: Neoplasms | Metastatic prostate cancer | C61 | AR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | APP |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3 |
| C00-D49: Neoplasms | Gastric cancer | C16 | EGFR; EGFR |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | ALOX5 |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | EGFR |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | AR |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Amyloidosis | E85 | APP |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis in post-menopausal women | M80-M81 | AR |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
| I00-I99: Diseases of the circulatory system | Ischemic reperfusion injury | I00-I99 | PRKCE |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | AR |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; TP53; FLT3; FLT3 |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3 |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | ALOX5; NOS2 |